-
Himalayan glacier study warns of flood and water-supply risks
-
Trump rejects AI slowdown concerns as UN urges coordinated controls
-
Kuwait schools restore classroom routines after remote learning
-
US judge postpones new visa rules for foreign students, journalists
-
US designer Bob Mackie, known for Hollywood glamour, dies at 87
-
Higher wages draw migrant workers to Kashmir despite attacks
-
BIS flags debt and profitability risks in AI-driven market rally
-
Oil supply concerns and AI warnings weigh on global markets
-
Qatar Chamber and Maltese envoy consider business forum
-
'I am the hoax buster': Trump rejects AI danger warnings
-
Spanish PM denies being blackmailed by Morocco
-
Macklemore dropped from Ed Sheeran tour after 'free Palestine' speech
-
Doha Islamic finance forum names AlRayan firms as co-lead partners
-
Trump's son confirms Russian businessman paid for post-wedding festivities
-
Leeds thrash Newcastle to go third in the Premier League
-
Betis beat winless Villarreal to go third
-
Zelensky says Ukraine ready for 'de-escalatory steps'
-
Etihad capacity rises as war disruption weighs on annual earnings
-
In-form Malen fires Roma to Serie A summit, Inter on their heels
-
At G20 summit, US unravels power plant climate rules
-
Lebanese agency reports Israeli shelling and gunfire in south
-
Russian disinformation campaign sets sights on US midterms
-
Expert proposes phased digital reform for Arab business schools
-
England No 8 Pollock could move abroad or switch sports amid contract stand-off
-
Trump rejects 'hoax' warnings that AI could destroy humanity
-
Canada makes pitch as safe place to invest in 'uncertain world'
-
Houthis say Saudi Arabia hits Yemen with 54 strikes after attack on bases
-
In-form Malen fires Roma to Serie A summit
-
Why the far right is losing ground in Sweden
-
IOC visits Lyon amid leadership turmoil for 2030 Winter Olympics
-
Ex-Ireland fly-half O'Gara extends deal as La Rochelle coach
-
New York seizes 12 celeb deep-fake porn sites
-
Russian attacks on Ukraine railways escalating every week: rail CEO to AFP
-
Jesse Eisenberg channels emotional intensity into 'The Debut'
-
France, Iraq deepen energy, defence ties during Zaidi visit
-
Alarm over AI grows as divided US Congress struggles to act
-
Trump says Ukraine, Russia agree not to hit energy targets
-
PopDEX Surpasses $61M TVL and $2B Trading Volume in Closed Beta
-
Nigeria's Dangote refinery launches continent's biggest IPO
-
Oasis announce new 2027 world tour
-
Trump blasts 'sick conspiracy' against AI as warnings mount
-
Women athletes condemn 'sexualised' Sydney Sweeney commercial
-
For Laura Linney, role in Parkinson's-themed movie marked a turning point
-
UN calls for 'urgent action' to rein in AI in face of 'unprecedented risks'
-
Doctors face life sentence over Greek pop star's death
-
Russia intensifies attacks seeking to intimidate Ukraine, Europe
-
Trump moves to axe power plant climate rules
-
Richarlison not in Spurs League Cup squad: De Zerbi
-
Slow the AI race? Investors weigh the potential cost
-
French defence group Thales calls on governments to regulate AI
Pharma-Bio Serv Announces Results for the Quarter Ended July 31, 2026
DORADO, PR / ACCESS Newswire / September 14, 2026 / Pharma-Bio Serv, Inc. ("Pharma-Bio Serv" or the "Company") (OTCQB:PBSV), a compliance, project management and technology transfer support consulting firm today announced that revenues for the three and nine months ended July 31, 2026 were approximately $2.3 million and $7.3 million, respectively, representing increases of approximately $0.4 million and $0.5 million compared to the same periods last year.
For the three and nine months ended July 31, 2026, the Company reported a net loss of $14 thousand and net income of approximately $252 thousand, respectively, representing improvements of approximately $190 thousand and $352 thousand, respectively, compared with the corresponding periods of the prior year.
"Our Q3 results demonstrate the strength of our client relationships and the value of our specialized regulatory and compliance capabilities. By sharpening our focus on markets where our expertise creates a distinct competitive advantage and continuing to drive operating efficiencies, we meaningfully improved our financial performance. We remain confident in our ability to build on this progress and carry that momentum through the final quarter of the year," said Victor Sanchez, Chief Executive Officer.
About Pharma-Bio Serv, Inc.
Pharma-Bio Serv provides services to the pharmaceutical, biotechnology, chemical, medical device, cosmetic, food and allied products industries to Puerto Rico, United States, Europe and Brazil markets. Pharma-Bio Serv's core business is FDA and international agencies regulatory compliance consulting related services. The Company's global team includes leading engineering and life science professionals, quality assurance managers and directors.
Forward-Looking Statements
This news release contains "forward-looking statements" within the meaning of the U.S. federal securities laws, which statements may include information regarding the plans, intentions, expectations, future financial performance, or future operating performance of Pharma-Bio Serv. Forward-looking statements are based on the expectations, estimates, or projections of management as of the date of this earnings announcement. Although Pharma-Bio Serv's management believes these expectations, estimates, or projections to be reasonable as of the date of this earnings announcement, forward-looking statements are inherently subject to significant business risks, economic uncertainties, and competitive uncertainties, and other factors, which could cause its actual results or performance to differ materially from what may be expressed or implied in the forward-looking statements. Important factors that could cause Pharma-Bio Serv's actual results or performance to differ materially from the forward-looking statements include those set forth in the "Risk Factors" section of Pharma-Bio Serv's Annual Report on Form 10-K for the year ended October 31, 2025, and in its other filings with the Securities and Exchange Commission, which filings are available at www.sec.gov. Pharma-Bio Serv disclaims any intention or obligation to update or revise any forward-looking statements to reflect subsequent events and circumstances, except to the extent required by applicable law.
Company Contact:
Pedro J. Lasanta
Chief Financial Officer
787-278-2709
SOURCE: Pharma-Bio Serv Inc.
View the original press release on ACCESS Newswire
O.Ortiz--AT